Get the Daily Brief
Latest Biotech News
Sarepta's Duchenne Gene Therapy Under Regulatory Scrutiny and Shipment Pause
Sarepta Therapeutics is facing mounting challenges surrounding its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. After three patient deaths linked to liver failure, including a case...
FDA and Biotech Leadership Changes Amid Increasing Regulatory Challenges
The FDA has appointed George Tidmarsh, a seasoned biotech executive and Stanford professor, as director of the Center for Drug Evaluation and Research (CDER), a key leadership role during a period...
Replimune’s Melanoma Therapy Faces FDA Rejection
The FDA has issued a complete response letter rejecting Replimune Group’s oncolytic virus therapy RP1 for advanced melanoma, citing inadequate and poorly controlled clinical studies that failed to...
Advances in Cancer and Immunotherapy Research
Recent studies and clinical trials are shedding new light on cancer biology and immunotherapy. Key findings include the identification of transfer RNA-derived small RNAs impairing NK cell function...
Neuralink Hits Milestone with Two Brain Implants in One Day
Neuralink announced it has successfully performed two brain-computer interface implant surgeries in a single day, bringing the total number of human participants to nine. This achievement advances...
Genomic Editing and Conservation Biology
An international scientific team proposed using gene editing to restore genetic diversity in endangered species by leveraging historical DNA samples from museum specimens, biobanks, and related...
Innovations in AI and Bioinformatics for Drug Discovery
Jura Bio introduced VISTA, an AI data loop system for large-scale de novo antibody design, addressing gaps in functional annotation crucial for drug discovery. The system synergizes genomic...
Alkermes Advances Narcolepsy Treatment with Positive Phase 2 Data
Alkermes reported positive Phase 2 trial results for its orexin receptor agonist, alixorexton, in patients with narcolepsy type 1, demonstrating statistically significant improvements in...
Sanofi Expands Respiratory Vaccine Pipeline: $1.15B Vicebio Buyout
Sanofi is set to acquire Vicebio Ltd., a privately held UK biotech specializing in respiratory virus vaccines, for $1.15 billion upfront with up to $450 million in potential milestone payments....
Sarepta Therapeutics Faces FDA Safety Crisis Over Duchenne Gene Therapy
Sarepta Therapeutics has temporarily halted shipments of its Duchenne muscular dystrophy gene therapy Elevidys following safety concerns tied to three patient deaths linked to acute liver failure....
FDA Names George Tidmarsh to Lead CDER Amid Drug Review Challenges
The FDA appointed George Tidmarsh, an accomplished biotech executive and Stanford professor with expertise spanning oncology and pediatrics, as director of its Center for Drug Evaluation and...
Replimune’s Melanoma Virus Therapy Gets FDA Rejection, Shares Drop 75%
Replimune Group’s application for approval of RP1, a viral-based treatment for advanced melanoma, was rejected by the FDA for inadequate and uncontrolled clinical investigation and trial design...
Omega Funds Closes $647 Million Biotech Venture Capital Fund
Omega Funds closed its eighth investment fund, raising $647 million targeted at U.S. and European life sciences companies addressing unmet medical needs. The fund nearly matched the size of the...
Neuralink Hits Double Brain Implant Milestone, Eyes 20 Procedures by Year-End
Neuralink has performed two brain-computer interface implants in a single day for the first time, advancing its total human implants to nine and pushing toward a goal of 20 procedures by the end...
Pancreatic Cancer Stress Pathway Identified for Early Detection Opportunities
Researchers discovered a molecular pathway used by pancreatic cancer cells to adapt to stress and inflammatory conditions, which could serve as an early warning system for aggressive pancreatic...
Asia-Pacific Biotechs Drive Innovation in Extracellular Vesicle Drug Delivery
Biotech startups in the Asia-Pacific region are pioneering the use of extracellular vesicles (EVs) for drug delivery, leveraging their low immunogenicity, natural tissue targeting, and ability to...
Single-Cell Study Reveals Mechanisms of Nasopharyngeal Cancer Radioresistance and Immune Escape
A Chinese research team applied integrated single-cell and spatial transcriptomic techniques to characterize molecular features of recurrent nasopharyngeal carcinoma (rNPC), uncovering key...
Sanofi Bolsters Respiratory Vaccine Pipeline With $1.15 Billion Vicebio Buy
Sanofi announced a $1.15 billion acquisition of London-based biotechnology company Vicebio, including potential milestone payments up to $450 million, to expand its respiratory virus vaccine...
Sarepta Faces FDA Scrutiny, Halts Duchenne Therapy Shipments Amid Safety Concerns
Sarepta Therapeutics has temporarily paused shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD), following an escalating standoff with the FDA. The FDA requested a halt...
FDA Rejects Replimune’s Melanoma Oncolytic Virus Therapy Amid Regulatory Shift
The FDA issued a complete response letter rejecting Replimune Group’s oncolytic virus drug for advanced melanoma, citing inadequate single-arm trial design and patient heterogeneity. The agency...